Loading…
Novo Nordisk A/S is projected to rise to $49.37 by 2027, a +11% move from its current price of $44.55. NVO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $43.84 | $44.57 | $45.32 | +0.05% |
| May 30 | $43.57 | $44.60 | $45.66 | +0.11% |
| May 31 | $43.36 | $44.62 | $45.92 | +0.16% |
| Jun 1 | $43.19 | $44.65 | $46.15 | +0.22% |
| Jun 2 | $43.05 | $44.67 | $46.36 | +0.28% |
| Jun 3 | $42.92 | $44.70 | $46.55 | +0.33% |
| Jun 4 | $42.80 | $44.72 | $46.73 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $42.80 | $44.72 | $46.73 | +0.39% |
| Week 2 | $42.19 | $44.89 | $47.77 | +0.77% |
| Week 3 | $41.77 | $45.07 | $48.62 | +1.16% |
| Week 4 | $41.44 | $45.24 | $49.39 | +1.55% |
| Week 5 | $41.17 | $45.41 | $50.10 | +1.94% |
| Week 6 | $40.94 | $45.59 | $50.76 | +2.33% |
| Week 7 | $40.75 | $45.77 | $51.40 | +2.73% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Novo Nordisk A/S is a healthcare company that, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S (NVO) is a healthcare stock trading at $44.96. It has a market cap of $199.25B and is ranked 70.
The forecast suggests a rising price outlook over time. The 2026 average price is $44.96, with a path that climbs toward higher levels in later years (e.g., 2027 avg $49.87, 2028 avg $52.24, 2029 avg $53.55, 2030 avg $57.39, 2040 avg $122.69, 2050 avg $200.15).
Forecasts show a bullish drift from 2030 onward, with max values climbing from $78.41 in 2030 to $327.53 in 2050. Max values include 2030 $78.41, 2040 $187.36, and 2050 $327.53.
A major floor 21.8% below — a decisive break under it would weaken the trend.
The nearest floor, 13.5% below — buyers have tended to step in here.
The nearest ceiling, 5.7% above — a clean break opens room to run.
A major ceiling 43.6% above — clearing it would confirm fresh momentum.
Key NVO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NVO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $44.63 | Sell | $44.60 | Sell |
| MA 10 | $44.93 | Sell | $44.71 | Sell |
| MA 20 | $44.80 | Sell | $44.15 | Buy |
| MA 50 | $40.81 | Buy | $43.06 | Buy |
| MA 100 | $45.27 | Sell | $44.68 | Sell |
| MA 200 | $49.01 | Sell | $50.75 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.45 | Neutral |
| Stoch RSI (14) | 8.12 | Buy |
| CCI (20) | -15.49 | Neutral |
| Williams %R (14) | -87.54 | Info |
| MACD (12,26,9) | -0.33 | Sell |
| ROC (12) | -3.30 | Sell |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 12.46 | Buy |
| TRIX (15) | 0.49 | Buy |
| Awesome (5,34) | 1.94 | Buy |
| Ultimate (7,14,28) | 47.51 | Neutral |
| Momentum (10) | -2.45 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 44.46 | Buy |
| ADX (14) | 24.42 | Buy |
| ATR (14) | 0.63 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 60.
The short-term moving averages show SMA50 at $40.56 and SMA200 at $49.06. The 30-day trading range stretches from $40.14 to $50.36.
Near-term support sits at $37.98 and resistance at $47.08.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $35.29 | $44.55 | $57.85 | 0% | Neutral | |
| $40.33 | $49.37 | $63.25 | +11% | Neutral | |
| $42.01 | $52.36 | $68.84 | +18% | Neutral | |
| $42.33 | $53.57 | $71.89 | +20% | Bullish | |
| $44.70 | $57.31 | $78.28 | +29% | Bullish | |
| $53.40 | $69.29 | $96.12 | +56% | Bullish | |
| $57.05 | $74.86 | $105.31 | +68% | Bullish | |
| $58.69 | $77.81 | $110.86 | +75% | Bullish | |
| $61.72 | $82.64 | $119.13 | +86% | Bullish | |
| $60.91 | $82.32 | $119.98 | +85% | Bullish | |
| $88.63 | $124.93 | $190.76 | +180% | Bullish | |
| $134.77 | $203.70 | $333.31 | +357% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $35.29 | $44.55 | $52.22 | +0.00% |
| June 2026 | $39.44 | $46.01 | $54.71 | +3.27% |
| July 2026 | $39.92 | $46.84 | $56.23 | +1.81% |
| August 2026 | $39.26 | $46.27 | $55.95 | -1.21% |
| September 2026 | $39.24 | $46.41 | $56.45 | +0.30% |
| October 2026 | $39.94 | $47.41 | $57.98 | +2.15% |
| November 2026 | $39.74 | $47.31 | $58.13 | -0.21% |
| December 2026 | $39.26 | $46.87 | $57.85 | -0.92% |
Click any year to see its month-by-month NVO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NVO is projected to trade between $35.29 and $57.85, averaging $44.55 — a potential gain of 0% from today's $44.55. Price action looks broadly range-bound.
Novo Nordisk A/S's 2027 outlook centres on $49.37, within a $40.33 to $63.25 range. That is up +11% on the projected 2026 average. That marks a +11% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, NVO could reach as high as $68.84, with a base case around $52.36 and support toward $42.01 — roughly +18% from $44.55. Price action looks broadly range-bound.
Expect NVO to range from $42.33 to $71.89 through 2029. The $53.57 average target implies a +20% move from current prices. That is up +2% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The NVO price prediction for 2030 points to an average of $57.31 (low $44.70, high $78.28) — a potential gain of +29% on today's $44.55. Momentum favours further upside here.
In 2031, NVO is projected to trade between $53.40 and $96.12, averaging $69.29 — a potential gain of +56% from today's $44.55. That is up +21% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Novo Nordisk A/S's 2032 outlook centres on $74.86, within a $57.05 to $105.31 range. That is up +8% on the projected 2031 average. That marks a +68% change versus current levels. Momentum favours further upside here.
By 2033, NVO could reach as high as $110.86, with a base case around $77.81 and support toward $58.69 — roughly +75% from $44.55. Buyers look set to stay in control over this stretch.
Expect NVO to range from $61.72 to $119.13 through 2034. The $82.64 average target implies a +86% move from current prices. That is up +6% on the projected 2033 average. Momentum favours further upside here.
The NVO price prediction for 2035 points to an average of $82.32 (low $60.91, high $119.98) — a potential gain of +85% on today's $44.55. Buyers look set to stay in control over this stretch.
In 2040, NVO is projected to trade between $88.63 and $190.76, averaging $124.93 — a potential gain of +180% from today's $44.55. That is up +52% on the projected 2035 average. Momentum favours further upside here.
Novo Nordisk A/S's 2050 outlook centres on $203.70, within a $134.77 to $333.31 range. That is up +63% on the projected 2040 average. That marks a +357% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in NVO today (≈ 22.446689 NVO) could be worth
$4,572.36
+$3,572.36 (+357%) by 2050 · US Dollar
Based on the average projected NVO price of $203.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NVOwould be worth at today's price.
$1,000 invested in NVO on May 27, 2025 (≈ 14.196479 NVO) would be worth
$632.45
-$367.55 (-36.8%) today · 0.63× · US Dollar
Based on a NVO entry price of $70.44 vs. today's $44.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $45.07 | $988.46 | -1.2% |
| 1 month ago | $41.2 | $1,081.31 | +8.1% |
| 3 months ago | $37.62 | $1,184.21 | +18.4% |
| 6 months ago | $49.35 | $902.74 | -9.7% |
| 1 year ago | $70.44 | $632.45 | -36.8% |
| All time (5.0y) ago | $39.6 | $1,125.14 | +12.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NVO forecast.
Our base-case forecast reaches $89.00 around 2040.
Implied market cap at $89.00: $298.67B
The multi-year forecast depicts a transition from neutral to bullish sentiment, with notable upside potential beginning in 2030. In 2030 the avg price is $57.39, with a min of $44.75 and a max of $78.41, and a predicted ROI of 27.6%.
From 2031 to 2035 the outlook remains bullish, with 2031 avg $68.76 (max $95.40, ROI 52.9%), 2032 avg $74.45 (max $104.74), 2033 avg $77.33 (max $110.19), 2034 avg $81.69 (max $117.79), and 2035 avg $81.67 (max $119.05).
The longer horizon shows substantial upside: 2040 avg $122.69 (max $187.36, ROI 172.9%), and 2050 avg $200.15 (max $327.53, ROI 345.2%). The sentiment in 2040 and 2050 is BULLISH.
Tap a question to reveal the answer.
The forecast shows min $44.75, avg $57.39, max $78.41, ROI 27.6%, sentiment BULLISH.
The outlook shifts from NEUTRAL in 2026–2029 to BULLISH from 2030 onward, with rising averages (2030 $57.39; 2040 $122.69; 2050 $200.15) and increasing max values (2030 $78.41; 2040 $187.36; 2050 $327.53). ROIs rise through the horizon (e.g., 2027 10.9%, 2028 16.2%, 2029 19.1%, 2030 27.6%, 2031 52.9%, 2050 345.2%). These are estimates, not guarantees.
Yes. The forecast shows several years with max values above $100, including 2032 max $104.74, 2033 max $110.19, 2034 max $117.79, 2035 max $119.05, and 2040 max $187.36, with 2050 max $327.53.
Current price is $44.96 and market cap is $199.25B.
RSI14 is 60, with SMA50 at $40.56 and SMA200 at $49.06. The 30-day range is $40.14 to $50.36, with support at $37.98 and resistance at $47.08.
Novo Nordisk A/S Community Discussion
0Share your Novo Nordisk A/S price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.